A patient (OG) with Glanzmann thrombasthenia became refractory to platelet transfusion after the production of an immunoglobulin G (IgG) isoantibody (Abl) specific for the integrin subunit /33. To determine the frequency at which the OG idiotype is found in the general population and in immune-mediated disease states, we developed a rabbit polyclonal antibody (Ab2) specific for affinity-purified OG anti-/33 Fab. The binding of Ab2 to Abl is inhibited by purified 0lI1b/33; Ab2 also binds to IgG specific for 0/Iib/33 obtained from one nonrelated Glanzmann thrombasthenia patient ES who has developed isoantibodies of similar specificity. On the other hand, Ab2 does not recognize cqrb/33-specific antibodies produced by two Glanzmann thrombasthenia patients, AF and LUC, who have developed isoantibodies with specificities distinct from that of the OG isoantibody. Moreover, Ab2 does not recognize oqro/33-specific antibodies developed by three representative patients with (autoimmune) thrombocytopenic purpura or six representative patients with alloimmune thrombocytopenias, nor does it bind to IgG from any of 13 nonimmunized individuals. We have found that Ab2 also binds to selected protein ligands of Cqlb/33 namely, fibrinogen, vitronectin, and von Willebrand factor, but not to other protein ligands or control proteins, such a fibronectin, type I collagen, and albumin. The epitope(s) recognized by Ab2 on each adhesive protein are either very similar or identical since each protein can inhibit the binding of Ab2 to any of the other proteins. The epitope on fibrinogen recognized by Ab2 resides in the B/3 chain, and is likely contained within the first 42 amino acids from the NH2 terminus.
T
he integrin O~IIb/33 is probably the most immunogenic protein complex on the surface of human platelets. This generalization is based on the fact that it is the most frequently identified target of human autoantibodies in immune-mediated thrombocytopenia and immune-mediated platelet dysfunction (1) and that oqro/33 bears no less than five amino acid polymorphisms that are responsible for a majority of cases of platelet-specific alloimmunization among Caucasians (1) . In addition, patients with the inherited abnormality of O~IIb/33 known as Glanzmann thrombasthenia (GT) 1 tend to develop anti-c~ir~/33 antibodies (isoantibodies) after receiving blood transfusions to correct bleeding diatheses. Some of the isoantibodies react solely with the c~iro/33 complex (2), others are specific for either the CCiib (3) or the/33 subunits (4, 5).
Although GT isoantibodies are not the class of anti-otiibB3 antibodies most frequently encountered by the serology laboratory, they are of significant clinical and scientific interest since they can lead to a severe state of refractoriness to platelet transfusion therapy and because they generally recognize epitopes on c~tro33 that are involved in the adhesive function of this integrin.
We have recently defined the OG idiotype (Ishida, F., Y. Gruel, E. Brojer, D. J. Nugent, and T. J. Kunicki, manuscript submitted for publication) associated with IgG antibodies specific for the integrin B3 subunit produced by such a GT patient (OG) who suffered from persistent and often serious bleeding episodes as a result of his disease (6) . The frequency and severity of bleeding episodes in OG were far above the norm for this disease, presumably because this high titered, IgG antibody which proved to be in vitro an effective inhibitor of transfused platelets and thereby rendered therapeutic platelet intervention ineffective (4, 7) .
It is our contention that the characterization of the OG idiotype will lead to a better understanding of the mechanisms involved in immunization against the integrin cgiib33, both in the case of OG and in the case of other individuals, with or without GT. In this report, we use a highly specific, polyclonal anti-OG idiotype reagent (Ab2) to determine the distribution of antibodies bearing the OG idiotype among individuals immunized against olin,33 and normal volunteers. In addition, we provide evidence that Ab2 binds to epitopes common to three adhesive proteins recognized by otiib33, fibrinogen, vitronectin (Vn), and yon Willebrand factor (vWf).
Materials and Methods
Human IgG. The clinical history and laboratory findings of patient OG have been described (4, 7) (Ishida et al., manuscript submitted for publication). In Western blot assays and an antigen capture enzyme-linked immunoabsorbant assay, we consistently detect IgG in OG plasma that binds to free/33 (4) . This IgG (Abl) completely blocks fibrinogen binding to c~lrbB3 and thus platelet aggregation induced by ADP, thrombin, or other physiologic agonists (4, 7) . Other patients contributing to this study include three unrelated individuals with GT." patient ES, described by Coiler et al. (2) , has developed an IgG isoantibody that binds predominantly to the cqroB3 complex and does not cross-react with cevB3; IgG from patient LUC (8) is predominantly reactive with Cenb and, consequently, does not cross-react with cevB3; and IgG from patient AF (5) binds equally well to both ~IIb~3 and czvB3 and has been found to recognize an epitope(s) localized within B3324-422 (9) . Additional patients include six individuals who have developed plasma IgG Oqtb~3-specific alloantibodies, namely, three with antiPl ^1 antibodies (10, 11), GAS, KILO, and WHA; two with antiPen b (12, 13) alloantibodies, YuA and TRU; and one with anti-Pew antibodies, YuB (12); and three individuals diagnosed to have chronic (autoimmune) thrombocytopenic purpura who have developed 33-specific autoantibodies, RA, GER, and BER (14, 15) .
Comparative Binding of Human IgG Antibodies. Established procedures were used for purification of o~iroB3 (16) or cevB3 (17) . The amount of IgG in plasma or purified IgG fractions which binds to o~vB3 or cereS3 integrins was measured by ELISA. Briefly, 100 pl of 0.05 M sodium carbonate buffer, pH 9.6, containing 2 pg/ml of purified cxvB3 or c~lroB3 were added to each well of a microtiter plate, and plates were incubated at 4~ overnight to permit maximal adsorption of antigen. The plates were blocked with PBS/ Tween and rinsed three times; to each well were added 50 #1 of test human plasma (diluted 1:100 in PBS/Tween) or purified IgG (50/~g/ml), and the plates were incubated for 2 h at ambient temperature. The wells were washed three times with PBS/Tween, 50/~1 of alkaline phosphatase (AP)-conjugated goat anti-human IgG (heavy + light chain; Zymed Laboratories, Inc., San Francisco, CA) diluted 1:1,000 were added to each well, and plates were incubated at ambient temperature for 1 h. After five subsequent washes with PBS/Tween, the color reaction was initiated, and the OD at 405 nM was recorded as described above.
Purification of Abl. IgG was isolated from OG plasma by ammonium sulfate precipitation and DEAE cellulose chromatography, as described (18) , while Otnb•3 was purified from washed platelets according to the method of Fitzgerald et al. (16) . cqrd33-specific antibodies were affmity-purified by adsorption to Oqlb~3, coupled to CNBr-activated Sepharose 4B (1.5 mg antigen/ml beads; Pharmacia Fine Chemicals, Uppsala, Sweden). 2 ml of packed beads was incubated overnight at 4~ with 30 mg of OG IgG in 2 ml of 20 mM Tris, pH 7.4. Bound antibody was eluted by addition of 100 mM glycine, pH 3.0, and the eluate was neutralized by addition of 1.5 M Tris, pH 8.8. Fab were prepared by digestion of affmity-purified IgG with mercaptopapain (Sigma Chemical Co., St. Louis, MO) in PBS containing 10 mM cysteine and 2 mM ~, as described (14) . Intact IgG and Fc fragments were removed by protein A-Sepharose (Pharmacia Fine Chemicals) chromatography. Purity of Fab preparations was confirmed by SDS-PAGE.
Preparation ofRabM PolydonalAb2. Fab fragments of the purified OG IgG specific for Oqlb/33 were used to immunize two New Zealand White rabbits. For primary immunizations, each rabbit was injected subcutaneously in the back with 50 #g of affmitypurified OG Fab emulsified in CFA. Booster injections (50/~g) were given in incomplete Freund's adjuvant on day 7, 14, 35, and every 2 wk thereafter. Sera were collected from ear arteries on day 1, 21, and every 15 d thereafter. Sera were stored at 4~ before use. IgG was isolated from sera of immunized rabbits, as described above for human IgG, and adsorbed by successive passages over columns containing a 50-fold molar excess of normal human IgG plus IgM linked to Sepharose 4B (Pharmacia Fine Chemicals) a minimum of three times or until all detectable reactivity with isotypic or allotypic determinants was removed.
Specificity ofAb2for OG IgG. 50 pl of normal human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) or affinitypurified OG IgG in 0.05 M sodium carbonate buffer, pH 9.6, was added to each well of a microtiter plate (Immulon II; Dynatech Laboratories, Inc., Alexandria, VA), and plates were incubated at 4~ overnight. The wells were blotted dry, to each well were added 200/~1 of 67 mM NaHPO4, 67 mM Na2PO4, 150 mM NaC1, pH 7.4 containing 0.05% Tween 20 (PBS/Tween), and plates were incubated for I h at ambient temperature to block remaining binding sites. After three rinses with PBS/Tween, 50 ~1 of rabbit Ab2 (5 #g/ml in PBS/Tween) was added to each well, and plates were incubated for I h. The weUs were washed with PBS/Tween three more times, then to each well were added 50 pl of AP-conjugated goat anti-rabbit IgG (heavy + light chain; Zymed, Inc.), diluted 1:1,000 in PBS/Tween, and plates were incubated for 1 h. After an additional five washes, the color reaction was initiated, and the OD at 405 nm for each well was recorded at intervals using an automated microphte reader (EIA reader, model 255; Bio-Rad Laboratories, Richmond, CA).
ELISA Screen of Human lgG for 0 (7, Id. test sample was added to each well (in triplicate), and plates were incubated for 1 h at ambient temperature. The wells were rinsed six times with PBS/Tween, 50/~1 of affinity-purified Ab2 (4/~g/ml) was added to each well, and plates were incubated for 1 h. The wells were then washed with PBS/Tween three times, to each well was added 50/~1 of alkaline-phosphatase conjugated goat anti-rabbit IgG (Zymed, Inc.) diluted 1:1,000 in PBS/Tween, and plates were incubated for I h. After an additional five washes, the color reaction was initiated, and the OD at 405 nm of each well was recorded in an EIA reader (Bio-Rad Laboratories) at appropriate intervals (nominally, at 30 min).
Binding to Ab2 to Purified Proteins. Human plasma fibronectin
and type I collagen were purified as previously described (19, 20) . Human plasma vitronectin was purified as described (21) and was a gift from Dr. Brunhilde Felding-Haberman (l.aJolla, CA). Human plasma vWf, human fibrinogen (fraction I-2), fragment X, fragment D100, and fragment E were purified as described (22, 23) and generously provided by Dr. Zaverio Ruggeri (La Jolla, CA). To adsorb antigen, 50/~1 of carbonate buffer containing the purified protein was added to each well of a microtiter plate, and plates were incubated overnight at 4~ The concentrations of each protein that enabled maximal adsorption were determined beforehand and were: 2/~g/ml type I collagen; 5/~g/ml fibrinogen; 10/~g/ml fibronectin; 4/~g/ml fragment D100; 3 #g/ml fragment E; 7.5/~g/ml fragment X; 2/~g/ml vitronectin; and 5/~g/ml vWf. The wells were blocked with PBS/Tween, and after three rinses with PBS/ Tween, the binding of Ab2 (50 #1 vol containing 0-50/~g/ml in PBS/Tween) was measured as described above. In competition assays, 25 #1 of PBS/Tween containing the inhibitory protein at 0.2, 1, 2, 5, 10, 25, 50, or 100/~g/ml was added at the same time as Ab2, the mixtures were incubated for 2 h at ambient temperature, and the plates were processed as described above.
To assess the effect of selected fibrinogen-specific, murine monoclonal antibodies on the binding of Ab2 to fibrinogen, wells coated with fibrinogen, as described above, were then incubated with 100/~1 of routine antibody IgG in PBS/Tween for 2 h at ambient temperature. The wells were then rinsed three times, Ab2 (10/~g/ml in PBS/Tween) was added, the plates were incubated for an additional 2 h, and the reactions were assessed as described above. Murine IgG was added at a concentration of 1, 2.5, 5, or 25 #g/ml. The murine antibodies developed and characterized by Dr. Z. Ruggeri and co-workers (24, 25) are: anti-RGDS (LJ-134B29; anti-Ao~566-580); anti-IkGDF (LJ-155Bg; anti-Ac~87-100); anti-L10 (LJ-Z-69/8; anti-q,400-411); and anti-BB (LJ-33.4; specific for an unidentified epitope(s) in the NH2-terminal region).
Western Blot. The specificity of the antifibrinogen activity of Ab2 was further analyzed by Western blot (18) . SDS-PAGE was performed as previously described (18) using a Laemmli buffer system and 10% polyacrylamide resolving slab gels. Purified human fibrinogen (fractions I-2 and I-9), prepared as described (26) and generously provided by Dr. David Amrani (Milwaukee, WI), and fragment D100, were subjected to electrophoresis together with normal human Fab and OG Fab. Reduction was accomplished by addition of 5% 2-mercaptoethanol. After dectrophoresis, proteins were transferred to 0.2/~m pore-size nitrocellulose membranes (BioPad Laboratories) in the following manner. Acrylamide gels and membranes were equilibrated in transfer buffer (192 mM glycine, 25 mM "Iris, 20% methanol, pH 8.3), and transfer of proteins was accomplished at 30 V for 30 rain followed by 60 V for 3 h at 4~ After transfer, the remaining active sites of the nitrocellulose membrane were blocked by incubating the membrane in PBS/Tween containing 0.05% NaN3 and 1% nonfat dry milk. The membrane was then washed three times for 10 min each in PBS/Tween. The same buffer containing 1% nonfat dry milk was used to dilute the primary antibodies or the purified conjugated antibody. The membrane strips were incubated with the primary antibody, i.e., rabbit Ab2 or polyclonal rabbit anti-human fibrinogen (Dako Corp., Carpinteria, CA), overnight (16-20 h ) at room temperature with constant, gentle, orbital agitation. Then, strips were washed three times for 10 min and incubated with a 1:1,000 dilution of alkaline-phosphatase conjugated goat antibodies against rabbit IgG (heavy + light chain; Zymed, Inc.). After 2-3 h and three additional washes, the binding of this antibody was revealed by incubating the strips in freshly prepared substrate solution consisting of 66/~1 of a stock solution of nitroblue tetrazolium (50 mg/ml in 70% dimethylformamide) and 33 #1 of a stock solution of bromo-4-chloro-3-indolylphosphate (50 mg/ml in 100% dimethyl-formamide) in 10 ml of 100 mM Tris-HC1, 100 mM NaC1, 5 mM MgC12, pH 9.5. To stop color development, the membranes were rinsed in distilled water for 10 min and allowed to dry.
Peptides. Peptides were synthesized using F-moc chemistry and an automated peptide synthesizer (MilliGen/Biosearch, Burlington, MA) then purified by reverse-phase HPLC, as previously described (27) .
Results

Comparison of Human IgG that Bind c~ii~3. Both OG
and ES IgG bind weakly, if at all, to olv:/3 (Fig. 1) , unlike AF IgG and each of the aUoantibodies tested, namely GAS and KKO. Since OG IgG is known to bind to free :/3 in Western blot assays (4), two explanations for these findings are possible. Either the OG epitope(s) on :/3 is masked in the olv:/3 complex or there exist both :/3-reactive and c~iro:/3-restricted IgG antibodies. Because the anti-:/3 eluted from Western blot membranes binds to O/lib:/3 on intact platdets, and antibodies eluted from intact platdets or purified O~IIb:/3 bind solely to :t3 in subsequent Western blots (4), the latter explanation is not likely. The lack of binding of LUC IgG to 0l~:/3 is expected since it contains isoantibodies that predominantly bind O~llb (3, 8) . Moreover, the difference in binding of AF and OG (or ES) to Cl~v:/3 is alSO consistent with a difference in epitope location on :/3. While AF is now known to bind to epitopes located within :/3 324-422 was adsorbed onto wells of a microtiter tray at identical concentrations (2/~g/ml). Plasmas (suffix "p") or IgG (all others) from a group of donors known to contain ~XirbB3-reactive antibodies were allowed to incubate with antigen, then bound human IgG was detected with rabbit anti-human IgG. Of the donors tested, IgG from ES, LUC, and the propositus OG binds e~chsively or much more strongly to cqrbB3, while IgG from AF, GAS, and KR.O binds equally well to both O~llb~3 and otv/~3. In each case, the mean _+ SD is depicted (for oqn,B3, n = 4; for ~v3s, n = 2). As a negative control, the lack of binding oflgG from normal subjects (C) is conspicuous (for Oqlb33, n = 10; for otvB3, n = 2). antibodies that are classified Ab23, i.e., those that mimic antigen epitopes and block the binding of Abl to antigen. To determine the extent to which the OG idiotype is used by oLlro33-specific antibodies from other individuals, we tested the binding of Ab2 to IgG in sera, plasmas, and IgG preparations from nonimmunized volunteers and persons who have been previously determined to have developed antibodies against c~in,133 as a result of auto-, allo-, or isoimmunization (Fig. 3 A) . From this preliminary screening, it is evident that Ab2 binds to a restricted subset of human antibodies reactive with oeiib33, i.e., only those antibodies generated by certain individuals with the hereditary disorder GT. The presence of the OG idiotype (OG and ES positive; AF, LUC, and remaining donors negative) correlates well with the observed binding properties of IgG from these donors (Fig. 1) . Thus, the OG idiotype-positive individuals, OG and ES, are the sole subjects whose IgG antibody binds to 83 but also distinguishes cx[roB3 from (Xv~3. When patient IgG is permitted to bind to c~irJ33-coated microtiter plates (Fig. 3 B) , significant levels of O/IIb~3 ~ specific antibody are bound, as detected with rabbit antihuman IgG (solid bars). However, bound OG idiotype-positive IgG (OG or ES IgG) cannot be detected by the rabbit antiidiotype Ab2, presumably because Ab2B antiidiotypes, which are the predominant component of this antiidiotype reagent, cannot access the specific paratopes once they are in contact with antigen. However, OG IgG eluted from otiib~3-coated microtiter plates, is strongly bound by Ab2 in subsequent ELISA (4).
Peptide and MAb Competition. The binding of OG IgG
(Abl) to o~3 is not inhibited by either the peptide RGDW or the "y-chain decapeptide L10 (Fig. 4 A) , even when peptide concentrations as high as 2 mM were used. As a control, specific inhibition of mAb OPG2 by KGDW was observed (IDs0 =6 #M). Of six Oqlb/33-specific mAb tested, OG IgG 2263 Gruel et al. strongly inhibited the binding of only 7E3 or OPG2 (Fig.  4 B) , two IgG mAb known to bind to distinct sites within the fibrinogen recognition pocket of Otlro33. 7E3 and OPG2 are both complex-dependent mAb. As controls, no inhibition of the binding of the complex-specific mAb AP2 (epitope unknown), AP5 (anti-/331-5), SZ21 (anti-3327-32), or LIBS2 (anti-/33602-690) was observed. Although not tested here, ES IgG has also been shown to significantly inhibit the binding of 7E3 to ~xlro/33 (2) .
As shown in Fig. 5 , Ab2 also binds to fibrinogen, vWf and vitronectin but not to fibronectin, collagen type I, or the control protein, albumin. The binding of Ab2 to any one of these three adhesive proteins is completely inhibited by either of the remaining two (Fig. 6) , suggesting that Ab2 recognizes cross-reactive or identical epitopes on these three proteins.
We previously determined that the binding of Abl to o+t~l~,.+ could not be inhibited by KGD-containing peptides, such as KGDW, or the carboxyl-terminal decapeptide of the fibrinogen gamma A chain (L10) (Fig. 4) . Likewise, the binding of Ab2 to fibrinogen is not inhibited by any of three murine monodonal antibodies specific for the three putative integrin binding sites on this molecule, namely RGDS and RGDF on the Ac~ chain or LIO (Fig. 7 A) . These findings are supported by a comparison of the binding of Ab2 to intact fibrinogen and its major plasmin-derived fragments. Thus, in comparison to intact fibrinogen, Ab2 binds less strongly to fragment X and not at all to fragment D or fragment E (Fig. 7 B) . Finally, by Western blot assay, Ab2 binds preferentially to a protein band whose electrophoretic mobility is consistent with that of the B/3 chain (Fig. 8) .
Since the differential binding of Ab2 to fibrinogen fragments and the results ofimmunoblot assays suggest that Bfl15-42 might participate in epitopes recognized by Ab2, we tested the ability of three overlapping B3 peptides, B/315-28, B/324-33, and B332-42, to inhibit binding of Ab2 to either fibrinogen or vitronectin. None of the three peptides inhibits Ab2 binding even at concentrations as high as 2 mM (data not shown). 2264 Further Characterization of the Thrombasthenia-related Idiotype OG 
Discussion
Since the initial description of the idiotype network, there has been a great deal of interest in the potential role of this network in the regulation of the immune response and in the exploitation of antiidiotypes for the development of vaccines or inhibitors of the immune response, because certain antiidiotypes bear the "internal images" of the primary antigen (28) . Yet another interesting and practical application of antiidiotypes stems from the capacity of antiidiotypes to mimic functional protein recognition site(s) of the primary antigen. Anti-Id antibodies are classified into four major categories, Ab2cz, -fl, -% and -e, but only Ab2fl, which bind to the paratope (28) of Abl and carry the internal image of the antigen, or Ab2% which recognize antigen combiningsite-associated idiotopes, are able to interfere with the interaction of Abl with antigen. In this study, we conclude that Ab2 contains predominantly Ab2fl and/or Ab2y, because purified CXnbB3 inhibits the binding of Ab2 to OG IgG, and Ab2 is precluded from binding to Abl when Abl is bound to OeHbfl3. This conclusion is supported by the finding that Ab2 binds strongly to an epitope(s) common to three physiologic ligands of r i.e., fibrinogen, vWf, and Vn. Since OG isoantibody binds to B3 and inhibits ADP-or thrombin-induced plat, let aggregation, it is likely that it binds close to or at recognition site(s) on f13 for fibrinogen. There are two loci on f13 that have been implicated as fibrinogen contact sites. The first, flanking Asp119, is thought to engage the RGDS sequence of the fibrinogen Acx chain (29, 30) . The second, encompassing amino acids 209-222, is thought to interact with a different site on fibrinogen (31). Our results indicate that the OG isoantibody (Abl) does not bind to either of these loci. First, neither RGD-containing peptides nor our murine monoclonal antibody OPG2 (32) , which contains an P, YD sequence and binds to the first recognition site on ~3, inhibit the binding of OG isoantibody. Second, our murine monoclonal IgM antibody AP6 (33) , which binds to the sequence ~3 209-222, also fails to inhibit the binding of OG isoantibody. Third, by comparing the binding of OG isoantibody to recombinant human ~3, Xenopus/33, and several chimeras of human 133:Xenolous~3, we have found that the epitope recognized by OG isoantibody is determined by sequences within residues 7-53 of ~3 (S. Honda, Y. Honda, and T. J. Kunicki, unpublished observation).
The fact that the putative adhesive sequences of fibrinogen, i.e., RGDS (Acx 572-575) or L10 (decapeptide "y402-411) are not involved is supported by ELISA results wherein Ab2 binds to fibrinogen fragment X which does not contain the o~ COOH-terminal P, GDS site, and Ab2 binding to human fibrinogen is not inhibited by murine monodonal antibodies specific for either Aol 566-580 (encompassing RGDS), Acx 87-100 (encompassing RGDF), or the 3' COOH-terminal decapeptide. Thus, the epitopes within fibrinogen recognized by Ab2 are distinct from the RGD sequences. We find common epitopes in Vn and vWf. By ELISA, the binding of Ab2 to Vn or vWf is stronger than that observed with fibrinogen, and the epitopes on Vn and vWf are similar if not identical to those fibrinogen, since any one of these proteins is able to completely inhibit the binding of Ab2 to the other two. Other RGD-containing ligands, namely, collagen type I and fibronectin, are not recognized by Ab2, consistent with the conclusion that Ab2 binds to RGD-independent sequences.
Without further localization of the cross-reactive regions on the fibrinogen B3 chain, Vn, or vWf, it is not possible to precisely identify the epitopes for Ab2 solely by sequence homologies even if a few homologous short acid sequences are present. We will use a number of approaches to further localize the epitopes in question, including screening of random peptide libraries to find sequences that bind with high affinity to Ab2 and testing of additional proteolytic fragments of the fibrinogen B3 chain or well-defined fibrinogen variants. Nonetheless, our results, in light of the fact that OG IgG inhibits platelet aggregation and fibrinogen binding and Ab2 mimics the primary antigen, support the hypothesis that the Bfl chain is involved in the fibrinogen binding to platelet OelroB3 in a manner that has not yet been characterized.
Ab2 reacts solely with OG isoantibodies (Abl) and czlr~33-specific isoantibodies from a second GT patient ES. In the limited comparison of four GT patient isoantibodies conducted in this study, ES IgG and OG IgG have the most similar specificities, with respect to Oqibl33 and oLv133. On the other hand, the two idiotype-negative IgG isoantibodies, from patients AF and LUC, exhibit specificities different from one another and from ES or OG IgG. Thus, it is not surprising that the antiidiotype reagent can distinguish ES and OG IgG from the remaining two isoantibodies. In addition, Ab2 never binds to IgG from nonimmunized volunteers or to other c~Ird33-specific human IgG antibodies that were generated through different immune mechanisms, e.g., alloimmunization or autoimmunity.
The finding that Ab2 binds to ES IgG indicates that these two unrelated GT patients have independently generated antibodies of similar specificity which share a common idiotype. It has not been logistically feasible to measure direct competition between OG IgG and ES IgG since that would require substantial quantities of affinity-purified, labeled IgG, and these human antibodies are a limited resource. Additional evidence that ES and OG share the OG idiotype derives from the observation of Coller et al. (2) that ES IgG blocks the binding to c~iro/33 of the mAb 7E3. In this study, we further establish a dose relationship between ES IgG and OG IgG by showing that the latter also inhibits binding of 7E3 to oelrol33. Moreover, we show that OG IgG also blocks the binding of our mAb OPG2. 7E2 and OPG2 are effective inhibitors of fibrinogen binding to human platelets, and 7E3 is the first mAb of its kind to be tested in humans in vivo, as an inhibitor of thrombus formation (34, 35). The epitope(s) recognized by 7E3, OPG2, ES IgG, and OG IgG are obviously of biological and clinical relevance, and are at least spatially related.
Since Ab2 binds to the BB chain of fibrinogen, our study raises the possibility that a site(s), likely located within BB1-42, makes contact with a recognition site on/33, one that is defined by the OG epitope(s). Although there has not yet been any report of an interaction of the fibrinogen Bfl chain with r or any other integrin, Hamaguchi et al. (36) have demonstrated that platelet spreading on fibrin is mediated by a site within Bfl15-42. The receptor on endothelial cells that recognizes this site is bdieved to be a 130-kD surface protein not related to the integrins (37). We found that three overlapping peptides representing sequences within Bfl15-42 had no effect on the binding of Ab2 to fibrinogen or vitronectin. However, this negative result does not conclusively rule out that the epitope is present in this region of the Bfl chain, since the true epitope may be more complex than a simple linear sequence. Further studies are clearly warranted.
The OG idiotype is the first idiotype to be described that is associated with human IgG inhibitors of c~iibfl3 function. Since the antibodies bearing this idiotype bind so closely to the ligand recognition pocket of c~ird33, it is not unexpected that antiidiotypic antibodies should bind to ligands that interact with this recognition pocket. However, it is truly serendipitous and significant that each of the molecular interactions involved in this idiotype network, i.e., binding of OG idiotype to oqrd33, OG idiotype to antiidiotype, and antiidiotype to protein ligands, is mediated by a protein recognition motif that is independent of any ligand:c~abfl3 interaction yet defined. Our findings represent an excellent example of the manner in which the characterization of the molecular basis of an immune response and the underlying idiotype network can substantially improve our understanding of biologically relevant protein:protein recognition mechanisms.
